Viventia Bio is developing next generation oncology therapeutics utilizing our proprietary Targeted Protein Therapeutic technology (TPT). Our novel TPTs have been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates.

from http://www.viventia.com/about/company-overview

Publications show all

Viventia Bio has published 5 articles.

Patents show all

36Applications31Issued

Clinical Trials show all

2Phase 21Phase 11Phase 2/Phase 31Phase 3